Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.

Foreign compound-metabolizing enzymes may modify the risk of chemically induced cancer. We wanted to examine enzymes with putative relevance in urinary bladder cancer using molecular genetic analyses of heritably polymorphic enzymes. Arylamine N-acetyltransferase (NAT2); glutathione S-transferases (GSTs) M1 and T1; microsomal epoxide hydrolase; and cytochrome P-450 enzymes (CYP) 1A1, 2C19, 2D6, and 2E1 were analyzed in 374 cases and in 373 controls in a hospital-based case-control study in Berlin. Slow acetylation was a significant risk factor in heavy smokers [odds ratio (OR), 2.7; 95% confidence interval (CI), 1.0-7.4], with the greatest risk noted for the allele NAT2*5B. GSTM1 deficiency was a risk factor independent of smoking and occupation (OR, 1.6; CI, 1.2-2.2). GSTT1 was associated with cancer risk in the nonsmoker subgroup (OR, 2.6; CI, 1.1-6.0). The two amino acid polymorphisms that are known in microsomal epoxide hydrolase were not associated with bladder cancer risk. CYP2D6 activity was rejected as a risk factor by phenotyping and by detailed molecular genetic analyses. CYP2C19 may have a role in bladder cancer risk, but polymorphisms in CYP1A1 and 2E1 had no statistically significant impact. Deficiencies in both NAT2 and GSTM1 failed to show significant synergistic or antagonistic interactions. In conclusion, molecular genetic analysis of a large sample specified the increased bladder cancer risk of those who are deficient in NAT2 and GSTM1; the other traits proved to be of minor impact.

[1]  J. Brockmöller,et al.  Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. , 1996, Cancer research.

[2]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[3]  D. Bell,et al.  Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. , 1995, Cancer research.

[4]  T. Rustan,et al.  Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. , 1995, Cancer research.

[5]  G. Taubes.  Epidemiology faces its limits. , 1995, Science.

[6]  J. Brockmöller,et al.  Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. , 1995, Pharmacogenetics.

[7]  K. Buetow,et al.  Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[9]  A. Risch,et al.  Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. , 1995, Human molecular genetics.

[10]  R. Hoover,et al.  Debrisoquine metabolism and lung cancer risk. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  E. Messing,et al.  Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. , 1994, Carcinogenesis.

[12]  G. Clark,et al.  Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. , 1994, Pharmacogenetics.

[13]  R. Branch,et al.  Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. , 1994, Carcinogenesis.

[14]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[15]  D. Grant,et al.  Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. , 1994, Pharmacogenetics.

[16]  H. Bolt,et al.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. , 1994, The Biochemical journal.

[17]  K. Husgafvel‐Pursiainen,et al.  Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. , 1994, Carcinogenesis.

[18]  J. Idle,et al.  The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. , 1994, Pharmacogenetics.

[19]  J. S. Sidhu,et al.  Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. , 1994, Human molecular genetics.

[20]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  W. Humphreys,et al.  Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Pearson,et al.  Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. , 1993, BMJ.

[23]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[24]  K. Nakachi,et al.  Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.

[25]  R. Hayes,et al.  N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. , 1993, Carcinogenesis.

[26]  R. Rylander,et al.  Genetic polymorphism of cytochrome P4502E1 in a Swedish population , 1993, FEBS letters.

[27]  K. Nakachi,et al.  The CYP1A1 gene and cancer susceptibility. , 1993, Critical reviews in oncology/hematology.

[28]  A. Boddy,et al.  The pharmacogenetics of chemical carcinogenesis. , 1992, Pharmacogenetics.

[29]  E. Messing,et al.  Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[30]  J. Chang-Claude,et al.  Life style and occupational risk factors for bladder cancer in Germany. A case‐control study , 1992, Cancer.

[31]  S. Heckbert,et al.  Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. , 1992, Journal of the National Cancer Institute.

[32]  W. Pearson,et al.  Nomenclature for human glutathione transferases. , 1992, The Biochemical journal.

[33]  K. Kawajiri,et al.  Genetic Polymorphisms in the 5 '-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P 45011 E 1 Gene ' , 2008 .

[34]  P. Vineis,et al.  Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. , 1991, Pharmacogenetics.

[35]  F. Gonzalez,et al.  A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. , 1991, Carcinogenesis.

[36]  J. Idle,et al.  Is environmental carcinogenesis modulated by host polymorphism? , 1991, Mutation research.

[37]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[38]  P Vineis,et al.  Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. , 1991, Archives of environmental health.

[39]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[40]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[41]  T. Deguchi,et al.  Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. , 1990, The Journal of biological chemistry.

[42]  A. Llerena,et al.  Polymorphic oxidation of debrisoquine in bladder cancer. , 1990, Annals of medicine.

[43]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[44]  K. Kelsey,et al.  Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. , 1990, Cancer research.

[45]  A. Somogyi,et al.  Simultaneous Determination of Dextromethorphan and Three Metabolites in Plasma and Urine Using High‐Performance Liquid Chromatography with Application to Their Disposition in Man , 1990, Therapeutic drug monitoring.

[46]  R. Pero,et al.  Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. , 1990, Carcinogenesis.

[47]  R N Hoover,et al.  Occupational risks of bladder cancer in the United States: I. White men. , 1989, Journal of the National Cancer Institute.

[48]  O. Mcbride,et al.  Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. , 1988, Biochemistry.

[49]  W. Pearson,et al.  Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[52]  I. Roots,et al.  Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. , 1988, Klinische Wochenschrift.

[53]  R. Branch,et al.  Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. , 1987, Cancer research.

[54]  P. Hartge,et al.  Familial and environmental interactions in bladder cancer risk , 1985, International journal of cancer.

[55]  W. Weber,et al.  N-acetylation pharmacogenetics. , 1985, Pharmacological reviews.

[56]  M. Hetzel,et al.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer , 1984, Nature.

[57]  P. Philip,et al.  Genetically determined debrisoquine oxidation capacity in bladder cancer. , 1984, Carcinogenesis.

[58]  A. Conney,et al.  Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. , 1982, Cancer research.

[59]  R. Glashan,et al.  ROLE OF N-ACETYLTRANSFERASE PHENOTYPES IN BLADDER CARCINOGENESIS: A PHARMACOGENETIC EPIDEMIOLOGICAL APPROACH TO BLADDER CANCER , 1982, The Lancet.

[60]  H. Wolf,et al.  N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark , 1979, Environmental health perspectives.

[61]  E. Miller.  Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. , 1978, Cancer research.

[62]  B. Ames,et al.  Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.